Retreatment after benign prostatic hyperplasia (BPH) procedures appear lowest for men undergoing simple prostatectomy, HoLEP, ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...

This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.

List includes medications for diabetes, cancer, arthritis, and more ...

Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer.

The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of federal price ...

A scientific study suggests that weight loss drugs could reduce the risk of several cancers associated with obesity.